[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-detail-355698-en":3,"detail-sidebar-cat-0-en-105":51,"doc-seo-355698-105":98},{"code":4,"msg":5,"data":6},0,"success",{"doc_id":7,"user_id":8,"nickname":9,"user_avatar":10,"doc_module":4,"category_id":11,"category_name":12,"doc_title":13,"doc_description":14,"doc_content":15,"file_id":16,"file_url":17,"file_type":18,"file_size":19,"view_count":20,"is_deleted":4,"is_public":21,"is_downloadable":21,"audit_status":21,"page_count":22,"language":23,"language_code":24,"site_id":25,"html_lang":24,"table_of_contents":26,"faqs":27,"seo_title":28,"seo_description":14,"update_tm":29,"read_time":30,"preview_page_count":31,"preview_urls":32},355698,2336475401981,"Chumphorn","https://ap-avatar.wpscdn.com/avatar/22000c94efd8d5204d?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786935347598174694",8,"Research & Report","Colorectal Cancer - A Landscape of New Potential Radiopharmaceuticals - Molecular Diagnosis & Therapy 2026","Recent advances in imaging have supported a gradual, promising reduction in colorectal cancer mortality, with positron emission tomography (PET) using 2-deoxy-2-[fluorine-18]fluoro-d-glucose ([18F]FDG) as a key non-invasive tool. Its routine use for initial diagnosis or staging is constrained by radiotracer pharmacokinetics, limited specificity, and false positives from benign inflammatory conditions. New radiotracers targeting cancer hallmarks are under active development, with only [68Ga]Ga-HNI01 and [68Ga]Ga-FAPI-04 reaching preliminary clinical evaluation. Larger trials are needed to confirm efficacy, safety, and improved detection for better outcomes.","Molecular Diagnosis & Therapy (2026) 30:403–426 [https://doi.org/10.1007/s40291-026-00839-4](https://doi.org/10.1007/s40291-026-00839-4)  \nColorectal Cancer: A Landscape of New Potential  \nRadiopharmaceuticals  \nVeronica Serena Cabitza1 · Pier Cesare Capponi2 · Irene Brusa1 · Fabrizio Vincenzi3 · Silvia Pasquini3 · Katia Varani3 · Luca Urso3,4 · Licia Uccelli3,4  \nReceived: 5 November 2025 / Accepted: 15 February 2026 / Published online: 10 March 2026 © The Author(s) 2026  \nAbstract  \nIn recent years, advancements in imaging techniques have contributed to a gradual yet promising reduction in colorectal cancer-related mortality. Among these, positron emission tomography (PET), particularly in combination with computed tomography using 2-deoxy-2-[fluorine-18]fluoro-d-glucose ([18F]FDG), has emerged as a valuable non-invasive diagnostic tool. However, the application of [ 18F]FDG-PET in colorectal cancer remains limited because of the radiotracer’spharmacokinetics and metabolic characteristics. As a result, [ 18F]FDG-PET is not routinely recommended for the initial diagnosis or staging of colorectal cancer but is primarily used for assessing treatment response and disease surveillance. Additionally, colorectal cancer imaging with [ 18F]FDG presents challenges related to false-positive results caused by radiotracer uptake in non-malignant conditions such as inflammatory bowel disease, polyps, Crohn’s disease, and colitis. This inability to reliably distinguish between benign and malignant lesions remains a significant limitation in colorectal cancer imaging. To overcome these challenges, ongoing research is focused on the development of novel radiotracers capable of improving the specificity and accuracy of PET imaging in colorectal cancer. New radiolabeled probes are being investigated, including natural molecules, inflammatory markers, and target-specific immune elements, labeled with [ 18F],[68Ga],[ 11C], and [64Cu], which have shown potential in preclinical studies. Among emerging radiopharmaceuticals for colorectal cancer, only [68Ga]Ga-HNI01 and [68Ga]Ga-FAPI-04 have advanced to preliminary clinical evaluation phases. Despite promising initial diagnostic performance, these investigations remain limited in scale and scope, necessitating further rigorous, largescale clinical trials to validate efficacy and safety. All these advancements could significantly enhance colorectal cancer detection and characterization, leading to earlier diagnoses and better patient outcomes.  \nVeronica Serena Cabitza, Pier Cesare Capponi are co-first authors.  \n* Fabrizio Vincenzi [fabrizio.vincenzi@unife.it](fabrizio.vincenzi@unife.it)  \n* Silvia Pasquini [silvia.pasquini@unife.it](silvia.pasquini@unife.it)  \n1 Nuclear Medicine, IRCCS Azienda OspedalieroUniversitaria di Bologna, Bologna, Italy  \n2 Radiopharmaceutical Chemistry Section, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy  \n3 Department of Translational Medicine, University of Ferrara, Via Fossato di Mortara 17-19, 44121 Ferrara, Italy  \n4 Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria di Ferrara, Ferrara, Italy  \n1 Introduction  \nAmong gastrointestinal malignancies, colorectal cancer (CRC) represents a major health concern, ranking as the second leading cause of cancer-related deaths and the third most commonly diagnosed cancer worldwide, accounting for approximately 10% of all cancer cases [1] . Early detection is crucial, as localized CRC has a 5-year survival rate of around 91% . However, once metastasis occurs, particularly to the liver, the survival rate drops dramatically to approximately 15%. The pattern of CRC metastasis varies depending on the primary tumor site: colon cancer typically spreads first to adjacent regional and retroperitoneal lymph nodes, with occasional direct liver involvement, while rectal cancer, owing to its dense vascular network, can metastasize hematogenously to the lungs at an early stage [1] . This heterogeneity underscores the comple","cbCainr8lGehMue5","https://ap.wps.com/l/cbCainr8lGehMue5","pdf",2260704,10,1,24,"English","en",105,"# Abstract\n# Introduction\n# Key Points","[{\"question\":\"Why is [18F]FDG-PET not routinely recommended for initial CRC diagnosis or staging?\",\"answer\":\"[18F]FDG-PET is limited by pharmacokinetics and low specificity, with false-positive results arising from non-malignant inflammatory conditions.\"},{\"question\":\"What is the main limitation of colorectal cancer imaging using [18F]FDG?\",\"answer\":\"[18F]FDG can uptake in benign lesions, making it difficult to reliably distinguish between benign and malignant disease.\"},{\"question\":\"Which emerging radiotracers have reached preliminary clinical evaluation for CRC?\",\"answer\":\"Among emerging radiopharmaceuticals, [68Ga]Ga-HNI01 and [68Ga]Ga-FAPI-04 have advanced to preliminary clinical evaluation phases.\"}]","Colorectal Cancer - A Landscape of New Potential Radiopharmaceuticals - Molecular Diagnosis & Therapy 2026 | PDF",1790120527,60,4,[33,37,42,47],{"page_no":21,"url":34,"width":35,"height":36},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4b599fa192afa9fd112584020d80fb8c.webp",983,1305,{"page_no":38,"url":39,"width":40,"height":41},2,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/376903411bc187fb6cda17bc4eadb49b.webp",982,1304,{"page_no":43,"url":44,"width":45,"height":46},3,"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab0af1f1fe5ee06d3e623dbba9cff76e.webp",981,1303,{"page_no":31,"url":48,"width":49,"height":50},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/727a22c29701fec3a20fdfec5c11f7f6.webp",980,1301,{"code":4,"msg":5,"data":52},[53,58,62,66,70,75,80,83,88,91,94],{"id":21,"doc_module":4,"doc_module_name":54,"category_name":55,"show_sort_weight":56,"slug":57},"Document","Story & Novel",90,"story-novel",{"id":38,"doc_module":4,"doc_module_name":54,"category_name":59,"show_sort_weight":60,"slug":61},"Literature",80,"literature",{"id":31,"doc_module":4,"doc_module_name":54,"category_name":63,"show_sort_weight":64,"slug":65},"Exam",70,"exam",{"id":67,"doc_module":4,"doc_module_name":54,"category_name":68,"show_sort_weight":30,"slug":69},5,"Comic","comic",{"id":71,"doc_module":4,"doc_module_name":54,"category_name":72,"show_sort_weight":73,"slug":74},6,"Technology",50,"technology",{"id":76,"doc_module":4,"doc_module_name":54,"category_name":77,"show_sort_weight":78,"slug":79},7,"Healthcare",40,"healthcare",{"id":11,"doc_module":4,"doc_module_name":54,"category_name":12,"show_sort_weight":81,"slug":82},30,"research-report",{"id":84,"doc_module":4,"doc_module_name":54,"category_name":85,"show_sort_weight":86,"slug":87},9,"Religion & Spirituality",20,"religion-spirituality",{"id":86,"doc_module":4,"doc_module_name":54,"category_name":89,"show_sort_weight":86,"slug":90},"World Cup","world-cup",{"id":20,"doc_module":4,"doc_module_name":54,"category_name":92,"show_sort_weight":20,"slug":93},"Lifestyle","lifestyle",{"id":95,"doc_module":4,"doc_module_name":54,"category_name":96,"show_sort_weight":67,"slug":97},19,"General","general",{"code":4,"msg":99,"data":100},"ok",{"site_id":25,"language":24,"slug":101,"title":13,"keywords":102,"description":14,"schema_data":103,"social_meta":156,"head_meta":158,"extra_data":160,"updated_unix":161},"colorectal-cancer-a-landscape-of-new-potential-radiopharmaceuticals-molecular-diagnosis-therapy-2026","",{"@graph":104,"@context":155},[105,118,138],{"@type":106,"itemListElement":107},"BreadcrumbList",[108,112,114,116],{"item":109,"name":110,"@type":111,"position":21},"https://docshare.wps.com","Home","ListItem",{"item":113,"name":54,"@type":111,"position":38},"https://docshare.wps.com/document/",{"item":115,"name":12,"@type":111,"position":43},"https://docshare.wps.com/document/research-report/",{"item":117,"name":13,"@type":111,"position":31},"https://docshare.wps.com/document/colorectal-cancer-a-landscape-of-new-potential-radiopharmaceuticals-molecular-diagnosis-therapy-2026/355698/",{"url":117,"name":13,"@type":119,"image":120,"author":125,"headline":13,"publisher":127,"fileFormat":130,"inLanguage":24,"description":14,"dateModified":131,"datePublished":132,"encodingFormat":130,"isAccessibleForFree":133,"interactionStatistic":134},"DigitalDocument",{"url":121,"@type":122,"width":123,"height":124},"https://docshare.wps.com/thumbnails/colorectal-cancer-a-landscape-of-new-potential-radiopharmaceuticals-molecular-diagnosis-therapy-2026/355698.png","ImageObject",300,407,{"name":9,"@type":126},"Person",{"url":109,"name":128,"@type":129},"DocShare","Organization","application/pdf","2026-10-30","2026-09-22",true,{"@type":135,"interactionType":136,"userInteractionCount":20},"InteractionCounter",{"@type":137},"ViewAction",{"@type":139,"mainEntity":140},"FAQPage",[141,147,151],{"name":142,"@type":143,"acceptedAnswer":144},"Why is [18F]FDG-PET not routinely recommended for initial CRC diagnosis or staging?","Question",{"text":145,"@type":146},"[18F]FDG-PET is limited by pharmacokinetics and low specificity, with false-positive results arising from non-malignant inflammatory conditions.","Answer",{"name":148,"@type":143,"acceptedAnswer":149},"What is the main limitation of colorectal cancer imaging using [18F]FDG?",{"text":150,"@type":146},"[18F]FDG can uptake in benign lesions, making it difficult to reliably distinguish between benign and malignant disease.",{"name":152,"@type":143,"acceptedAnswer":153},"Which emerging radiotracers have reached preliminary clinical evaluation for CRC?",{"text":154,"@type":146},"Among emerging radiopharmaceuticals, [68Ga]Ga-HNI01 and [68Ga]Ga-FAPI-04 have advanced to preliminary clinical evaluation phases.","https://schema.org",{"og:url":117,"og:type":157,"og:title":13,"og:site_name":128,"og:description":14},"article",{"robots":159,"canonical":117},"index,follow",{"doc_id":7,"site_id":25},1790144152]